BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND KRAS, C-K-RAS, 3845, P01116, NS3, KI-RAS, KRAS2, K-RAS4A, K-RAS2A, K-RAS4B, KRAS1, K-RAS2B, RASK2 AND Treatment
2415 results:

  • 1. Epidemiological and clinicopathological features of kras, NRAS, BRAF mutations and MSI in Chinese patients with stage I-III colorectal cancer.
    Wang W; Wang R; Han X; Zhang W; Zhu L; Gu Y
    Medicine (Baltimore); 2024 Apr; 103(14):e37693. PubMed ID: 38579072
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Concurrent kras p.G12C mutation and ANK3::RET fusion in a patient with metastatic colorectal cancer: a case report.
    Bedau T; Heydt C; Siebolts U; Zander T; Kraemer M; Loeser H; Buettner R; Quaas A
    Diagn Pathol; 2024 Mar; 19(1):55. PubMed ID: 38539256
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Epigenetic MLH1 silencing concurs with mismatch repair deficiency in sporadic, naturally occurring colorectal cancer in rhesus macaques.
    Deycmar S; Johnson BJ; Ray K; Schaaf GW; Ryan DP; Cullin C; Dozier BL; Ferguson B; Bimber BN; Olson JD; Caudell DL; Whitlow CT; Solingapuram Sai KK; Romero EC; Villinger FJ; Burgos AG; Ainsworth HC; Miller LD; Hawkins GA; Chou JW; Gomes B; Hettich M; Ceppi M; Charo J; Cline JM
    J Transl Med; 2024 Mar; 22(1):292. PubMed ID: 38504345
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Efficacy of Chemotherapy Rechallenge Versus Regorafenib or Trifluridine/Tipiracil in Third-Line Setting of Metastatic colorectal cancer: A Multicenter Retrospective Comparative Study.
    Bazarbashi S; Alkhatib R; Aseafan M; Tuleimat Y; Abdel-Aziz N; Mahrous M; Elsamany S; Elhassan T; Alghamdi M
    JCO Glob Oncol; 2024 Mar; 10():e2300461. PubMed ID: 38484194
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Myotubularin-related-protein-7 inhibits mutant (G12V) K-RAS by direct interaction.
    Weidner P; Saar D; Söhn M; Schroeder T; Yu Y; Zöllner FG; Ponelies N; Zhou X; Zwicky A; Rohrbacher FN; Pattabiraman VR; Tanriver M; Bauer A; Ahmed H; Ametamey SM; Riffel P; Seger R; Bode JW; Wade RC; Ebert MPA; Kragelund BB; Burgermeister E
    Cancer Lett; 2024 Apr; 588():216783. PubMed ID: 38462034
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Concurrent NRAS-BRAF variants in metastatic colorectal cancer: a Tunisian case report.
    Douik H; Sahraoui G; Jemaà M; Doghri R; Charfi L; Mrad K
    Anticancer Drugs; 2024 Jun; 35(5):462-465. PubMed ID: 38451831
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Twelve-month progression-free survival with sotorasib and panitumumab in kras G12C mutant metastatic colorectal cancer.
    Kavgaci G; Dizdar O; Yalcin S
    Anticancer Drugs; 2024 Jun; 35(5):459-461. PubMed ID: 38451823
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Impact of carbamazepine on SMARCA4 (BRG1) expression in colorectal cancer: modulation by kras mutation status.
    Shaykevich A; Chae D; Silverman I; Bassali J; Louloueian N; Siegman A; Bandyopadhyaya G; Goel S; Maitra R
    Invest New Drugs; 2024 Apr; 42(2):229-239. PubMed ID: 38446332
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Improved survival of patients receiving immunotherapy and chemotherapy following curative-intent resection of colorectal liver metastases.
    Pollini T; Tran T; Wong P; Adam MA; Alseidi A; Corvera C; Hirose K; Nakakura E; Warren R; Maker VK; Maker AV
    J Gastrointest Surg; 2024 Mar; 28(3):246-251. PubMed ID: 38445916
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Morindone as a potential therapeutic compound targeting TP53 and kras mutations in colorectal cancer cells.
    Chee CW; Mohd Hashim N; Nor Rashid N
    Chem Biol Interact; 2024 Apr; 392():110928. PubMed ID: 38423379
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Current advances in targeted therapy for metastatic colorectal cancer - Clinical translation and future directions.
    Johnson D; Chee CE; Wong W; Lam RCT; Tan IBH; Ma BBY
    Cancer Treat Rev; 2024 Apr; 125():102700. PubMed ID: 38422896
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Tumor location matters, next generation sequencing mutation profiling of left-sided, rectal, and right-sided colorectal tumors in 552 patients.
    Ciepiela I; Szczepaniak M; Ciepiela P; Hińcza-Nowak K; Kopczyński J; Macek P; Kubicka K; Chrapek M; Tyka M; Góźdź S; Kowalik A
    Sci Rep; 2024 Feb; 14(1):4619. PubMed ID: 38409377
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Fusobacterium nucleatum promotes tumor progression in kras p.G12D-mutant colorectal cancer by binding to DHX15.
    Zhu H; Li M; Bi D; Yang H; Gao Y; Song F; Zheng J; Xie R; Zhang Y; Liu H; Yan X; Kong C; Zhu Y; Xu Q; Wei Q; Qin H
    Nat Commun; 2024 Feb; 15(1):1688. PubMed ID: 38402201
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Andrographolide sensitizes kras-mutant colorectal cancer cells to cetuximab by inhibiting the EGFR/AKT and PDGFRβ/AKT signaling pathways.
    Liu YF; Feng ZQ; Chu TH; Yi B; Liu J; Yu H; Xue J; Wang YJ; Zhang CZ
    Phytomedicine; 2024 Apr; 126():155462. PubMed ID: 38394734
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in
    Jansen RA; Mainardi S; Dias MH; Bosma A; van Dijk E; Selig R; Albrecht W; Laufer SA; Zender L; Bernards R
    Proc Natl Acad Sci U S A; 2024 Feb; 121(9):e2319492121. PubMed ID: 38377196
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Clinical features and mutation analysis of class 1/2/3 BRAF mutation colorectal cancer.
    Huang Y; Jia W; Zhao G; Zhao Y; Zhang S; Li Z; Wu G
    Chin Clin Oncol; 2024 Feb; 13(1):3. PubMed ID: 38372057
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer.
    Shitara K; Muro K; Watanabe J; Yamazaki K; Ohori H; Shiozawa M; Takashima A; Yokota M; Makiyama A; Akazawa N; Ojima H; Yuasa Y; Miwa K; Yasui H; Oki E; Sato T; Naitoh T; Komatsu Y; Kato T; Mori I; Yamanaka K; Hihara M; Soeda J; Misumi T; Yamamoto K; Yamashita R; Akagi K; Ochiai A; Uetake H; Tsuchihara K; Yoshino T
    Nat Med; 2024 Mar; 30(3):730-739. PubMed ID: 38347302
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Using tumor habitat-derived radiomic analysis during pretreatment
    Zhao H; Su Y; Wang Y; Lyu Z; Xu P; Gu W; Tian L; Fu P
    Cancer Imaging; 2024 Feb; 24(1):26. PubMed ID: 38342905
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Impacts of systemic treatments on health-related quality of life for patients with metastatic colorectal cancer: a systematic review and network meta-analysis.
    Jiang Y; Zhao M; Tang W; Zheng X
    BMC Cancer; 2024 Feb; 24(1):188. PubMed ID: 38336718
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. A pH-responsive cetuximab-conjugated DMAKO-20 nano-delivery system for overcoming K-ras mutations and drug resistance in colorectal carcinoma.
    Song H; Li H; Shen X; Liu K; Feng H; Cui J; Wei W; Sun X; Fan Q; Bao W; Zhou H; Qian L; Nie H; Cheng X; Du Z
    Acta Biomater; 2024 Mar; 177():456-471. PubMed ID: 38331131
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 121.